Simply Wall St.3d agoneutral
Is Recursion Pharmaceuticals (RXRX) A Bargain After Q3 Earnings And Clinical Updates?News
High-signal headlines only - macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.
105last 24h
3127last 7d
510● bullish (7d)
311● bearish (7d)
227publishers
Simply Wall St.4d agoneutral
REC 4881 Trial Results Could Change The Case For Recursion Pharmaceuticals StockSimply Wall St.4d agoneutral
Recursion Pharmaceuticals (RXRX) Puts Fred Hassan In The Chair After Phase 2 WinGuruFocus.com6d agoneutral
Earnings To Watch: Recursion Pharmaceuticals Inc (RXRX) Q3 2026 -- GF Value Sees 33% DownsideSimply Wall St.7d agoneutral
Recursion Pharmaceuticals (RXRX) Stock May Be Fully Priced As REC 4881 Data NearsGuruFocus.com9d agoneutral
Earnings To Watch: Recursion Pharmaceuticals Inc (RXRX) Q3 2026 -- GF Value Sees 35% DownsideGlobeNewswire13d agoneutral
Recursion to Host Webinar Focused on Updated REC-4881 (FAP) Data from CGA-IGC on Tuesday, November 3TechCrunch46d agoneutral
Enveda secures $311M to bring more nature-derived AI drugs into clinical trialsInsider Monkey47d agoneutral
Tempus AI (TEM) Has a $75 Goldman Sachs Target, But Its Data Business Faces a Bigger Test